A tumor microenvironment-related risk model for predicting the prognosis and tumor immunity of breast cancer patients

Abstract

BackgroundThis study aimed to construct a tumor microenvironment (TME)-related risk model to predict the overall survival (OS) of patients with breast cancer.MethodsGene expression data from The Cancer Genome Atlas was used as the training set. Differentially expressed gene analysis, prognosis analysis, weighted gene co-expression network analysis, Least Absolute Shrinkage and Selection Operator regression analysis, and Wald stepwise Cox regression were performed to screen for the TME-related risk model. Three Gene Expression Omnibus databases were used to validate the predictive efficiency of the prognostic model. The TME-risk-related biological function was investigated using the gene set enrichment analysis (GSEA) method. Tumor immune and mutation signatures were analyzed between low- and high-TME-risk groups. The patients’ response to chemotherapy and immunotherapy were evaluated by the tumor immune dysfunction and exclusion (TIDE) score and immunophenscore (IPS).ResultsFive TME-related genes were screened for constructing a prognostic signature. Higher TME risk scores were significantly associated with worse clinical outcomes in the training set and the validation set. Correlation and stratification analyses also confirmed the predictive efficiency of the TME risk model in different subtypes and stages of breast cancer. Furthermore, immune checkpoint expression and immune cell infiltration were found to be upregulated in the low-TME-risk group. Biological processes related to immune response functions were proved to be enriched in the low-TME-risk group through GSEA analysis. Tumor mutation analysis and TIDE and IPS analyses showed that the high-TME-risk group had more tumor mutation burden and responded better to immunotherapy.ConclusionThe novel and robust TME-related risk model had a strong implication for breast cancer patients in OS, immune response, and therapeutic efficiency.

Transcriptomic analysis identifies CYP27A1 as a diagnostic marker for the prognosis and immunity in lung adenocarcinoma

“…For example, new findings indicate that the diversity in the hierarchical malfunction of T-cell exhaustion can have an effect on the prognosis of cancer, offering the potential to utilize it as a reliable predictor of outcomes in cancer patients [ 41 ]. The newly developed and robust tumor microenvironment-related risk model had significant implications for breast cancer patients in terms of overall survival [ 42 ]. Tumor-infiltrating immune cells are vital components of the tumor microenvironment, actively contributing to both the response to tumor therapy and the progression of tumors [ 43 ].…”

Crosstalk between mitochondrial and lysosomal co-regulators defines clinical outcomes of breast cancer by integrating multi-omics and machine learning

“…Additionally, an extensive review of the pertinent literature from the past ve years was conducted. Subsequently, 18 signature genes associated with diverse biological processes, including exosome (13,14), TP53 mutation (15), necroptosis(16), depression (17), pyroptosis(18), autophagy (7,19), immune (20)(21)(22), angiogenesis (23), cuproptosis(18, 20), tumor microenvironment (TME) (24), methylation (25), natural killer cell (26), lipid metabolism (27), were incorporated for comparative analysis. The mlMSG prognostic model exhibited superior C-index performance compared to nearly all models present in TCGA and GEO datasets (Fig.…”

Development of a tumor microenvironment‐related prognostic signature in glioma to predict immune landscape and potential therapeutic drugs

“…[10,11] For example, it was reported that the context of TME such as the numbers of CD8 + T cells, CD4 + T cells, tumor-associated macrophages, dendritic cells, natural killer cells, and so forth, closely correlates to the prognosis of a variety of malignant tumors including lung cancer, gastric cancer, breast cancer, liver cancer and as well as glioma. [12][13][14][15] The latest research indicated how cancer cell disrupts the microenvironment in the normal stroma and promotes initiation, proliferation, invasion, metastasis, and angiogenesis in glioma development. [16] It is feasible to suppose that TME might link to the clinical outcome of glioma.…”